Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This study seeks to evaluate the safety, acceptability and feasibility of an outpatient "day procedure" for medical abortion at 13-18 weeks gestation in two public sector facilities. It also seeks to document the roles of health workers in providing services related to later abortion care and to document the costs of this day procedure to the health system.

See also
Status	Clinical Trial	Phase
Completed	`NCT02235155` - Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan	N/A
Completed	`NCT03710239` - OPIOID Study - Pain With Osmotic Dilators	N/A
Completed	`NCT01766388` - Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia	N/A
Completed	`NCT03346629` - Outpatient Service for Mid-trimester Termination of Pregnancy	Phase 4

NCT number	NCT05046041
Study type	Interventional
Source	Gynuity Health Projects
Contact
Status	Completed
Phase	Phase 4
Start date	November 25, 2020
Completion date	August 31, 2021

Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms